BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhang S, Yan L, Cui C, Wang Z, Wu J, Lv A, Zhao M, Dong B, Zhang W, Guan X, Tian X, Hao C. Downregulation of RRM2 Attenuates Retroperitoneal Liposarcoma Progression via the Akt/mTOR/4EBP1 Pathway: Clinical, Biological, and Therapeutic Significance. Onco Targets Ther 2020;13:6523-37. [PMID: 32753891 DOI: 10.2147/OTT.S246613] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Cui L, Tian X, Yan L, Guan X, Dong B, Zhao M, Lv A, Liu D, Wu J, Hao C. Expression and function of Siglec-15 in RLPS and its correlation with PD-L1: Bioinformatics Analysis and Clinicopathological Evidence. Int J Med Sci 2022;19:1977-88. [PMID: 36438917 DOI: 10.7150/ijms.77193] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Cui L, Yan L, Guan X, Dong B, Zhao M, Lv A, Liu D, Wang Z, Liu F, Wu J, Tian X, Hao C. Anti-Tumor Effect of Apatinib and Relevant Mechanisms in Liposarcoma. Front Oncol 2021;11:739139. [PMID: 34868934 DOI: 10.3389/fonc.2021.739139] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Xiong W, Zhang B, Yu H, Zhu L, Yi L, Jin X. RRM2 Regulates Sensitivity to Sunitinib and PD-1 Blockade in Renal Cancer by Stabilizing ANXA1 and Activating the AKT Pathway. Adv Sci (Weinh) 2021;8:e2100881. [PMID: 34319001 DOI: 10.1002/advs.202100881] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 6.5] [Reference Citation Analysis]